The effects of bortezomib treatment on these cytokines, which are key players in the cytotoxic and memory response mediated by CD8+ T cells and NK cells [36–38], suggest that bortezomib has the potential to influence the tumor microenvironment and host antitumor immunity. The gene discussed is CD8A; the disease is neoplasm.